US 4816567A
· Cabilly et al.
· 1989
[cited by applicant]
US 5194551A
· Clavier
· 1993
[cited by applicant]
US 5571894A
· Wels et al.
· 1996
[cited by applicant]
US 5587458A
· King et al.
· 1996
[cited by applicant]
US 5624821A
· Winter et al.
· 1997
[cited by applicant]
US 5731168A
· Carter et al.
· 1998
[cited by applicant]
US 5737056A
· Martin
· 1998
[cited by applicant]
US 5807706A
· Carter et al.
· 1998
[cited by applicant]
US 5821333A
· Carter et al.
· 1998
[cited by applicant]
US 5821337A
· Carter
· 1998
[cited by examiner]
US 5885573A
· Bluestone et al.
· 1999
[cited by applicant]
US 5937158A
· Uranaka
· 1999
[cited by applicant]
US 5968509A
· Gorman et al.
· 1999
[cited by applicant]
US 6054297A
· Carter
· 2000
[cited by examiner]
US 6331415B1
· Cabilly et al.
· 2001
[cited by applicant]
US 6627196B1
· Baughman et al.
· 2003
[cited by applicant]
US 6809185B1
· Schoonjans et al.
· 2004
[cited by applicant]
US 6949245B1
· Sliwkowski
· 2005
[cited by applicant]
US 7183076B2
· Arathoon et al.
· 2007
[cited by applicant]
US 7498142B2
· Yarden et al.
· 2009
[cited by applicant]
US 7635472B2
· Kufer et al.
· 2009
[cited by applicant]
US 7642228B2
· Carter et al.
· 2010
[cited by applicant]
US 7695936B2
· Carter et al.
· 2010
[cited by applicant]
US 7862817B2
· Adams et al.
· 2011
[cited by applicant]
US 7923221B1
· Cabilly et al.
· 2011
[cited by applicant]
US 7951917B1
· Arathoon
· 2011
[cited by applicant]
US 8193322B2
· Yan et al.
· 2012
[cited by applicant]
US 8592562B2
· Kannan et al.
· 2013
[cited by applicant]
US 8609095B2
· Pedersen et al.
· 2013
[cited by applicant]
US 8771988B2
· Goepfert et al.
· 2014
[cited by applicant]
US 9499634B2
· Dixit et al.
· 2016
[cited by applicant]
US 9574010B2
· Von Kreudenstein et al.
· 2017
[cited by applicant]
US 20030086924A1
· Sliwkowski
· 2003
[cited by applicant]
US 20040110226A1
· Lazar et al.
· 2004
[cited by applicant]
US 20070196363A1
· Arathoon et al.
· 2007
[cited by applicant]
US 20070274985A1
· Dubel et al.
· 2007
[cited by applicant]
US 20090182127A1
· Kjaergaard et al.
· 2009
[cited by applicant]
US 20100104564A1
· Hansen et al.
· 2010
[cited by applicant]
US 20110008345A1
· Ashman et al.
· 2011
[cited by applicant]
US 20120076728A1
· Wu et al.
· 2012
[cited by applicant]
US 20130078249A1
· Ast et al.
· 2013
[cited by applicant]
US 20130216523A1
· Wallweber et al.
· 2013
[cited by applicant]
US 20130245233A1
· Lei et al.
· 2013
[cited by applicant]
US 20170355779A1
· Wickman et al.
· 2017
[cited by applicant]
US 20200087414A1
· Kreudenstein et al.
· 2020
[cited by applicant]
EP 0368684A1
· 1990
[cited by applicant]
RU 2420537C2
· 2011
[cited by applicant]
WO WO1994004690A1
· 1994
[cited by applicant]
WO WO1996026964A1
· 1996
[cited by applicant]
WO WO1997034631A1
· 1997
[cited by applicant]
WO WVO1999058572A1
· 1999
[cited by applicant]
WO WO200100245A2
· 2001
[cited by applicant]
WO WO0100245A2
· 2001
[cited by examiner]
WO WO2004029207A2
· 2004
[cited by applicant]
WO WO2004032961A1
· 2004
[cited by applicant]
WO WO2007093630A1
· 2007
[cited by applicant]
WO WO2007110205A2
· 2007
[cited by applicant]
WO WO2009068625A2
· 2009
[cited by applicant]
WO WO2009068631A1
· 2009
[cited by applicant]
WO WO2009088805A2
· 2009
[cited by applicant]
WO WO2009089004A1
· 2009
[cited by applicant]
WO WO2009111707A1
· 2009
[cited by applicant]
WO WO2009134776A2
· 2009
[cited by applicant]
WO WO2009154651A1
· 2009
[cited by applicant]
WO WO2010085682A2
· 2010
[cited by applicant]
WO WO2010115553A1
· 2010
[cited by applicant]
WO WO2011005621A1
· 2011
[cited by applicant]
WO WO2011028952A1
· 2011
[cited by applicant]
WO WO2011117330
· 2011
[cited by applicant]
WO WO2011133886A2
· 2011
[cited by applicant]
WO WO2011143545A1
· 2011
[cited by applicant]
WO WO2011147982A2
· 2011
[cited by applicant]
WO WO2011147986A1
· 2011
[cited by applicant]
WO WO2012006635A1
· 2012
[cited by applicant]
WO WO2012058768A1
· 2012
[cited by applicant]
WO WO2012131555
· 2012
[cited by applicant]
WO WO2012143524A2
· 2012
[cited by applicant]
WO WO2012143523A1
· 2012
[cited by examiner]
WO WO2013002362A1
· 2013
[cited by applicant]
WO WO2013055958
· 2013
[cited by applicant]
WO WO2013135588A1
· 2013
[cited by applicant]
WO WO2013063702A1
· 2013
[cited by applicant]
WO WO2013166604A1
· 2013
[cited by applicant]
WO WO2014004586
· 2014
[cited by applicant]
WO WO2014060365A1
· 2014
[cited by applicant]
WO WO2014083208A1
· 2014
[cited by applicant]
WO WO2014144722A2
· 2014
[cited by applicant]
WO WO2015077891
· 2015
[cited by applicant]
WO WO2015091738A1
· 2015
[cited by applicant]
WO WO2016082044A1
· 2016
[cited by applicant]
WO WO2016179707A1
· 2016
[cited by applicant]
WO WO2017185177A1
· 2017
[cited by applicant]
Von Kreudenstein et al (mAbs, 2013, 5:646-654; published online Jul. 8, 2013) (IDS).
[cited by examiner]
U.S. Appl. No. 15/355,019 Non-Final Office Action dated Jan. 8, 2019.
[cited by applicant]
U.S. Appl. No. 15/355,019 Notice of Allowance dated Jul. 29, 2019.
[cited by applicant]
U.S. Appl. No. 15/355,019 Notice of Allowance dated May 22, 2018.
[cited by applicant]
Adams et al., “Humanization of a Recombinant Monoclonal Antibody to Produce a Therapeutic HER Dimerization Inhibitor, Pertuzumab,” Cancer Immunol Immunother, 2006, pp. 717-727, vol. 55, No. 6.
[cited by applicant]
Australian Notice of Acceptance for Australian Patent Application No. Au2014357292 dated Jun. 10, 2020 3 pages.
[cited by applicant]
Bargou et al. “Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody” Science Aug. 15, 2008 pp. 974-977 vol. 321.
[cited by applicant]
Bendig “Humanization of Rodent Monoclonal Antibodies by CDR Grafting” Methods: A Companion to Methods in Enzymology 1995; 8:83-93.
[cited by applicant]
Bohua et al., “Bispecific Antibody to ErbB2 Overcomes Trastuzumab Resistance through Comprehensive Blockade of ErbB2 Heterodimerization,” Cancer Research, vol. 73, No. 21, pp. 6471-6483, Sep. 17, 2013.
[cited by applicant]
Brodowicz et al., “Soluble HER-2/Neu Neutralizes Biologic Effects Of Anti-HER-2/Neu Antibody on Breast Cancer Cells In Vitro,” Int. J. Cancer, 1997, pp. 875-879, vol. 73.
[cited by applicant]
Brown et al. “Tolerance to Single but not Multiple Amino Acid Replacements in Antibody VHCDR2” The Journal of Immunology 1996 156:3285-3291.
[cited by applicant]
Bunn et al., “Expression of Her-2/neu in Human Lung Cancer Cell Lines by Immunohistochemistry and Fluorescence in Situ Hybridization and its Relationship to in Vitro Cytotoxicity by Trastuzumab and Chemotherapeutic Agen…
[cited by applicant]
Campiglio et al., “Inhibition of Proliferation and Induction of Apoptosis in Breast Cancer Cells by the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor ZD1839 ('Iressa') is Independent of EGFR Expressi…
[cited by applicant]
Carter et al., “Humanization of an Anti-p18SHERz Antibody for Human Cancer Therapy,” Proc. Natl. Acad. Sci. USA, May 15, 1992, pp. 4285-4289, vol. 89, No. 10.
[cited by applicant]
Casset et al. “A peptide mimetic of an anti-CD4 monoclonal antibody by rational design” BBRC 2003 307: 198-205.
[cited by applicant]
Cavazzoni et al., “Combined Use of Anti-ErbB Monoclonal Antibodies and Erlotinib Enhances Antibody-Dependent Cellular Cytotoxicity of Wild-Type Erlotinib-Sensitive NSCLC Cell Lines,” Molecular Cancer, 2012, pp. 91-115, …
[cited by applicant]
Chavez-Blanco et al., “HER2 Expression in Cervical Cancer as a Potential Therapeutic Target,” BMC Cancer, 2004, pp. 1-6, vol. 4:59.
[cited by applicant]
Chinese Office Action for Chinese Application No. 201480074300.2 dated Apr. 2, 2020 with English Translation 19 pages.
[cited by applicant]
Chmielewski et al., “T Cell Activation by Antibody-Like Immunoreceptors: Increase in Affinity of the Single-Chain Fragment Domain Above Threshold Does Not Increase T Cell Activation Against Antigen-Positive Target Cells…
[cited by applicant]
Cho et al., “Structure of the Extracellular Region of HER2 Alone and in Complex with the Herceptin Fab,” Nature, Feb. 13, 2003, pp. 756-760, vol. 421, No. 6924.
[cited by applicant]
Coldren et al., “Baseline Gene Expression Predicts Sensitivity to Gefitinib in Non-Small Cell Lung Cancer Cell Lines,” Mol Cancer Res., Jul. 28, 2006, pp. 521-528, vol. 4, No. 8.
[cited by applicant]
Collins et al., “Trastuzumab Induces Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) in HER-2-Non Amplifiedbreast Cancer Cell Lines,” Annals Oncology, 2001, pp. 1788-1795, vol. 23.
[cited by applicant]
Colman “Effects of amino acid sequence changes on antibody-antigen interactions” Research in Immunology1994 vol. 145: pp. 33-36.
[cited by applicant]
Cretella et al., “Trastuzumab Emtansine is Active on HER-2 Overexpressing NSCLC Cell Lines and Overcomes Gefitinib Resistance,” Molecular Cancer, 2014, pp. 143-155, vol. 13.
[cited by applicant]
Davis et al. “SEEDbodies: fusion proteins based on a strand-exchange engineered domain (SEED) Ch3 heterodimers in an Fe analogue platform for asymmetric binders or immunofusions and bispecific antibodies” Protein Engine…
[cited by applicant]
Decision to Grant Patent Application for Japanese Patent Application No. 2019-105971.
[cited by applicant]
Franklin et al., “Insights into ErbB Signaling from the Structure of the ErbB2-Pertuzumab Complex,” Cancer Cell, Apr. 2004, pp. 317-328, vol. 5.
[cited by applicant]
Fujimoto-Ouchi et al., “Antitumor Activity of Trastuzumab in Combination with Chemotherapy in Human Gastric Cancer Xenografl Models,” Cancer Chemother Pharmacol, 2007, pp. 795-805, vol. 59.
[cited by applicant]
Gaborit et al., “Time-Resolved Fluorescence Resonance Energy Transfer (TRFRET) to Analyze the Disruption of EGFR/HER2 Dimers: a New Method to Evaluate the Efficiency of Targeted Therapy Using Monoclonal Antibodies,” The…
[cited by applicant]
Garrett et al., “The Crystal Structure of a Truncated ErbB2 Ectodomain Reveals an Active Conformation, Poised to Interact with Other ErbB Receptors,” Molecular Cell, Feb. 2003, pp. 495-505, vol. 11, No. 2.
[cited by applicant]
Ghasemi et al., “Dual Targeting of ErbB-2/ErbB-3 Results in Enhanced Antitumor Activity in Preclinical Models of Pancreatic Cancer,” Oncogenesis, 2014, pp. 1-6, vol. 3.8, e117.
[cited by applicant]
Grazette et al., “Inhibition of ErbB2 Causes Mitochondrial Dysfunction in Cardiomyocytes,” Journal of the American College of Cardiology, Dec. 7, 2004, pp. 2231-2238, vol. 44, No. 11.
[cited by applicant]
Hayashi et al., :MP28-14: Targeting HER2 with Trastuzumab-DM1 (T-DM1) in HER2-overexpressing Bladder Cancer, Journal of Urology, May 18, 2014, 191 (4S) Supplement: e301.
[cited by applicant]
Hendriks et al., “Impact of Tumor HER2/ERBB2 Expression Level on HER2-Targeted Liposomal Doxorubicin-Mediated Drug Delivery: Multiple Low-Affinity Interactions Lead to a Threshold Effect,” Molecular Cancer Therapeutics,…
[cited by applicant]
HER2: Basic Research, Prognosis and Therapy, Yarden, Y, (ed.), IOS Press, 2000, 162 pages.
[cited by applicant]
Indian Examination Report for Indian Application No. 201647021238 dated Mar. 3, 2020 8 pages.
[cited by applicant]
Japanese Office Action for Japanese Patent Application No. 2017-528442 dated Nov. 8, 2019 with English translation 6 pages.
[cited by applicant]
Jost et al., “Structural Basis for Eliciting a Cytotoxic Effect in HER2-Overexpressing Cancer Cells Via Binding to the Extracellular Domain of HER2,” Structure, Nov. 5, 2013, pp. 1979-1991, vol. 21.
[cited by applicant]
Khantasup et al. “Design and Generation of Humanized Single-chain Fv Derived from Mouse Hybridoma for Potential Targeting Application” Monoclonal Antibodies in Immunodiagnosis and Immunotherapy 2015 34(6): 404-417.
[cited by applicant]
Kimura et al., “Antitumor Effect of Trastuzumab for Pancreatic Cancer with High HER-2 Expression and Enhancement of Effect by Combined Therapy with Gemcitabine,” Clin Cancer Res, Aug. 15, 2006, pp. 4925-4932, vol. 12, N…
[cited by applicant]
Komoto et al., “In Vitro and In Vivo Evidence That a Combination of Lapatinib plus S-1 is a Promising Treatment for Pancreatic Cancer—Komoto,” Cancer Science, Wiley Online Libra., Feb. 2010, pp. 468-473, vol. 101, No. 2.
[cited by applicant]
Kontermann, “Dual Targeting Strategies with Bispecific Antibodies,” mAbs, 2012, pp. 182-197, vol. 4, No. 2.
[cited by applicant]
Kuwada et al., “Effects of Trastuzumab on Epidermal Growth Factor Receptor-Dependent and -Independent Human Colon Cancer Cells,” Int J Cancer, 2004, pp. 291-301, vol. 109.
[cited by applicant]
Labrijn et al. “Efficient Generation of Stable Bispecific IgG1 by Controlled Fab-Arm Exchange,” Proc. Natl. Acad. Sci. USA, Mar. 26, 2013, pp. 5145-5150, vol. 110, No. 13.
[cited by applicant]
Larbouret et al., “In Pancreatic Carcinoma, Dual EGFR/HER2 Targeting with Cetuximab/Trastuzumab Is More Effective than Treatment with Trastuzumab/ Erlotinib or Lapatinib Alone: Implication of Receptors' Down-Regulation …
[cited by applicant]
Lazar et al. “Chapter 15: Engineering the Antibody Fe Region for Optimal Effector Function Therapeutic Monoclonal Antibodies: From Bench to Clinic” Z. An ed. John Wiley & Sons 2009 pp. 349-370.
[cited by applicant]
Lehmann et al., “Identification of Human Triple-Negative Breast Cancer Subtypes and Preclinical Models for Selection of Targeted Therapies,” The Journal of Clinical Investigation, 2011, pp. 2750-2767, vol. 121, No. 7.
[cited by applicant]
Li et al. “Genomic Analysis of Head and Neck Squamous Cell Carcinoma Cell Lines and Human Tumors: A Rational Approach to Preclinical Model Selection,” Mol Cancer Res, Apr. 2014, pp. 571-582, vol. 12, No. 4.
[cited by applicant]
Li et al., “Bispecific Antibody to ErbB2 Overcomes Trastuzumab Resistance Through Comprehensive Blockade of ErbB2 Heterodimerization,” Cancer Research, Sep. 17, 2013, pp. 6471-6483, vol. 73, No. 21.
[cited by applicant]
Ma et al., “HER2 as a Promising Target for Cytotoxicity T Cells in Human Melanoma Therapy,” PLOS One, Aug. 2013, pp. e73261-e73261, vol. 8, Issue 8.
[cited by applicant]
MacCallum et al., “Antibody-Antigen Interactions: Contact Analysis and Binding Site Topography,” J. Mol. Biol., 1996, pp. 732-745, vol. 262.
[cited by applicant]
Makhja et al., “Clinical Activity of Gemcitabine Plus Pertuzumab in Platinum-Resistant Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer,” Journal ofClincal Oncology, Mar. 1, 2010, pp. 1215-1223, vol. …
[cited by applicant]
McDonagh et al., “Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3,” Molecular Cancer Therapeutics, Mar. 2012, pp. 582-593,…
[cited by applicant]
Meira et al., “Combination of Cetuximab with Chemoradiation, Trastuzumab or MAPK Inhibitors: Mechanisms of Sensitisation of Cervical Cancer Cells,” British Journal of Cancer, 2009, pp. 782-791, vol. 101.
[cited by applicant]
Mexican Office Action for Mexican Application No. MX/a/2016006572 dated Jun. 1, 2020 with English Translation 7 pages.
[cited by applicant]
Nordstrom, “Anti-Tumor Activity and Toxicokinetics Analysis of MGAH22, and anti-HER2 Monoclonal Antibody with Enhanced Fe-Gamma Receptor Binding Properties,” Breast Cancer Research, Nov. 30, 2011, pp. 1-14, vol. 13, No.…
[cited by applicant]
Ohno et al. “Antigen-binding specificities of antibodies are primarily determined by seven residues of VH” Proc. Natl. Acad. Sci. USA May 1985 vol. 82: pp. 2945-2949.
[cited by applicant]
Patent Cooperation Treaty International Preliminary Report on Patentability International Patent Application No. PCT/CA2014/051140 Jun. 9, 2016.
[cited by applicant]
Patent Cooperation Treaty International Search Report and Written Opinion of the International Searching Authority International Patent Application No. PCT/CA2015/051238 Feb. 15, 2016 13 Pages.
[cited by applicant]
Patent Cooperation Treaty International Search Report and Written Opinion of the International Searching Authority International Patent Application No. PCT/CA2016/050546 Aug. 4, 2016 22 pages.
[cited by applicant]
Patent Cooperation Treaty International Search Report and Written Opinion of the International Searching Authority International Patent Application No. PCT/CA2017/050507 Aug. 16, 2017.
[cited by applicant]
Patent Cooperation Treaty, International Search Report and Written Opinion of the International Searching Authority, International Patent Application No. PCT/US2014/051140, Feb. 18, 2015, 18 Pages.
[cited by applicant]
Paul Fundamental Immunology 3rd Edition 1993 pp. 292-295.
[cited by applicant]
PCT/CA2014/051140 International Preliminary Report on Patentability issued Jun. 9, 2016.
[cited by applicant]
Phillips et al., “Dual Targeting of HER2-Positive Cancer with Trastuzumab-Emtansine (T-DM1) and Pertuzumab: Critical Role for Neuregulin Blockade in Anti-Tumor Response to Combination Therapy,” Clinical Cancer Research,…
[cited by applicant]
Plowman et al. “Ligand-Specific Activation of HER4/p18oerbs4, a Fourth Member of the Epidermal Growth Factor Receptor Family,” Proc. Natl. Acad. Sci., Mar. 1993, pp. 1746-1750, vol. 90.
[cited by applicant]
Prang et al., “Cellular and Complement-Dependent Cytotoxicity of Ep-CAMSpecific Monoclonal Antibody MT201 Against Breast Cancer Cell Lines,” British Journal of Cancer Research, 2005, pp. 342-349, vol. 92.
[cited by applicant]
Reddy et al. “Elimination of Fe receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4” J Immunol Feb. 15, 2000; 164(4): 1925-33.
[cited by applicant]
Repp et al. “Combined Fe-Protein and Fc-Glyco-Engineering of scFv-Fc Fusion Proteins Synergistically Enhances CD16a Binding but does not further enhance NK-Cell Mediated ADCC” Journal of Immunological Methods 2011 pp. 5…
[cited by applicant]
Ridgway et al. “‘Knobs-into-holes’ engineering of antibody Ch3 domains for heavy chain heterodimerization” Protein Engineering Jul. 1996 pp. 617-621 vol. 9 No. 7.
[cited by applicant]
Rudikoff et al., “Cellular and Complement-Dependent Cytotoxicity of Ep-CAMSpecific Monoclonal Antibody MT201 Against Breast Cancer Cell Lines,” British Journal of Cancer Research, 2005, pp. 342-349, vol. 92.
[cited by applicant]
Rudnick et al. “Influence of Affinity and Antigen Internalization on the Uptake and Penetration of anti-HER2 Antibodies in Solid Tumors,” Cancer Research, 2011, pp. 2250-2259, vol. 71, No. 6.
[cited by applicant]
Rusnack et al., “Assessment of Epidermal Growth Factor Receptor (EGFR, ErbB1) and HER2 (ErbB2) Protein Expression Levels and Response to Lapatinib (Tykerb®, GW572016) in an Expanded Panel of Human Normal and Rumour Cell…
[cited by applicant]
Seidman et al., “Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience,” Journal of Clinical Oncology, Mar. 1, 2002, pp. 1215-1221, vol. 20, No. 5.
[cited by applicant]
Semba et al., “A v-erbB-Related Protooncogene, c-erbB-2, is Distinct from the cerbB-1/Epidermal Growth Factor-Receptor Gene and is Amplified in a Human Salivary Gland Adenocarcinoma,” Proc. Natl. Acad. Sci., Oct. 1, 198…
[cited by applicant]
Shields et al. “High resolution mapping of the binding site on the human IgG1 for FcyRI FcyRIII and FcRn and design of IgG1 variants with improved binding to FcyR” Journal of Biological Chemistry Mar. 2, 2001 pp. 5591-6…
[cited by applicant]
Spreter Von Kreudenstein et al. “Protein engineering and the use of molecular modeling and simulation: The case of Heterodimeric Fe engineering” Methods 65(1): 77-94 (2014).
[cited by applicant]
Subik et al., “The Expression Patterns of ER, PR, HER2, CKS/6, EGFR, Ki-67 and AR by Immunohistochemical Analysis in Breast Cancer Cell Lines,” Breast Cancer: Basic Clinical Research, 2010, pp. 35-41, vol. 4.
[cited by applicant]
Suresh et al. “Bispecific monoclonal antibodies from hybrid hybridomas” Methods In Enzymol 121:210-28 (1983).
[cited by applicant]
Takai et al., “2C4, a Monoclonal Antibody Against HER2, Disrupts the HER Kinase Signaling Pathway and Inhibits Ovarian Carcinoma Cell Growth,” Cancer, Dec. 15, 2005, pp. 2701-2708, vol. 104, No. 12.
[cited by applicant]
Trail “Antibody Drug Conjugates as Cancer Therapeutics,” Antibodies, 2013, pp. 113-129, vol. 2.
[cited by applicant]
Traunecker et al. “Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells” EMBO J. Dec. 1991;10(12):3655-9.
[cited by applicant]
Tse et al., “HER2 Shedding and Serum HER2 Extracellular Domain: Biology and Clinical Utility in Breast Cancer,” Cancer Treatment Reviews, Apr. 2012, pp. 133-142, vol. 38, No. 2.
[cited by applicant]
U.S. Appl. No. 15/355,019 Notice of Allowance dated May 22, 2018 26 pages.
[cited by applicant]
U.S. Appl. No. 15/036,176—Non-Final Office Action dated Mar. 14, 2018 21 pages.
[cited by applicant]
U.S. Appl. No. 15/036,176—Non-Final Office Action dated Nov. 26, 2019.
[cited by applicant]
U.S. Appl. No. 15/036,176—Restriction Requirement dated Jul. 28, 2017.
[cited by applicant]
U.S. Appl. No. 15/036,176 Final Office Action dated Dec. 17, 2018.
[cited by applicant]
U.S. Appl. No. 15/411,799 Restriction Requirement dated Jan. 25, 2019.
[cited by applicant]
U.S. Appl. No. 15/526,888 Final Office Action Mar. 25, 2020 33 pages.
[cited by applicant]
U.S. Appl. No. 15/526,888 Non-Final Office Action Aug. 1, 2019 33 pages.
[cited by applicant]
U.S. Appl. No. 15/526,888 Restriction Requirement dated Oct. 9, 2018.
[cited by applicant]
U.S. Appl. No. 15/572,364—Restriction Requirement dated Feb. 7, 2020.
[cited by applicant]
U.S. Appl. No. 15/863,464—Notice of Allowance dated Apr. 20, 2018.
[cited by applicant]
U.S. Appl. No. 16/011,048 Non-Final Office Action Apr. 28, 2020 101 pages.
[cited by applicant]
U.S. Appl. No. 13/668,098—Final Office Action issued Nov. 17, 2015.
[cited by applicant]
U.S. Appl. No. 13/668,098—Non-final Office Action issued Apr. 3, 2015.
[cited by applicant]
U.S. Appl. No. 13/668,098—Notice of Allowance issued Sep. 23, 2016.
[cited by applicant]
U.S. Appl. No. 13/668,098—Restriction Requirement issued Dec. 5, 2014.
[cited by applicant]
U.S. Appl. No. 13/927,065—Final Office Action issued Feb. 22, 2016.
[cited by applicant]
U.S. Appl. No. 13/927,065—Non-final Office Action issued Oct. 7, 2015.
[cited by applicant]
U.S. Appl. No. 13/927,065—Notice of Allowance issued Aug. 26, 2016.
[cited by applicant]
U.S. Appl. No. 13/927,065—Restriction Requirement issued Apr. 15, 2015.
[cited by applicant]
U.S. Appl. No. 15/355,019—Non-Final Office Action issued Jul. 21, 2017.
[cited by applicant]
U.S. Appl. No. 15/355,019—Notice of Allowance issued Nov. 17, 2017.
[cited by applicant]
Vajdos et al. “Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis” J. Mol. Biol. 320:415-28 (Year: 2002)_.
[cited by applicant]
Von Kreudenstein et al., “Improving Biophysical Properties of a Bispecific Antibody Scaffold to Aid Developability Quality by Molecular Design,” MAPBS, Landes Bioscience, Sep. 1, 2013, pp. 646-654, vol. 5, No. 5.
[cited by applicant]
Von Kreudenstein et al., “Supplemental Material to: Improving Biophysical Properties of a Bispecific Antibody Scaffold to Aid Developability Quality by Molecular Design,” MAPBS, Landes Bioscience, Sep. 1, 2013, pp. 646-…
[cited by applicant]
Wang et al., Effect of Trastuzumab in Combination with IFN alpha-2b on HER2 and-MRP1 of ACHN. J Huazhong Univ Sci Technolog Med Sci. Jun. 2005; 25(3):326-8.
[cited by applicant]
Weidle et al., “The Intriguing Options of Multispecific Antibody Formats for Treatment of Cancer”, Cancer Genomics & Proteomics. 2013; 10(1):1-18.
[cited by applicant]
Winkler et al. “Changing the Antigen Binding Specificity by Single Point Mutations of an Anti-p24 (HIV-1) Antibody” The Journal of Immunology 2000 165: 4505-4514.
[cited by applicant]
Woods et al. “LC-MS characterization and purity assessment of a prototype bispecific antibody” MABS 5(5): 711-722 (2013).
[cited by applicant]
Xu et al.' ' “Diversity in the CDR3 Region of VH Is Sufficient for Most Antibody Specificities,” Immunity, Jul. 2000, pp. 37-45, vol. 13.
[cited by applicant]
Yamamoto et al., “Similarity of Protein Encoded by the Human c-erb-B-2 Gene to Epidermal Growth Factor Receptor,” Nature, Jan. 16-22, 1986, pp. 230-234, vol. 319, No. 6050.
[cited by applicant]
Zhou et al._' “Remodeling domain interfaces to enhance heterodimer formation” Protein Science vol. 6 No. 4 Apr. 1997 pp. 781-788.
[cited by applicant]